Last reviewed · How we verify

Low oxygenation target

Aalborg University Hospital · FDA-approved active Small molecule

A clinical protocol that maintains lower blood oxygen saturation targets during patient care to reduce hyperoxia-related complications.

A clinical protocol that maintains lower blood oxygen saturation targets during patient care to reduce hyperoxia-related complications. Used for Acute respiratory distress syndrome (ARDS), Critically ill patients requiring mechanical ventilation, Post-cardiac arrest care.

At a glance

Generic nameLow oxygenation target
Also known asInspired oxygen
SponsorAalborg University Hospital
ModalitySmall molecule
Therapeutic areaCritical Care / Intensive Care Medicine
PhaseFDA-approved

Mechanism of action

Low oxygenation target is a therapeutic strategy rather than a traditional drug, involving deliberate maintenance of lower oxygen saturation levels (typically 88-92%) in certain patient populations. This approach aims to minimize oxidative stress and inflammation associated with hyperoxia while avoiding hypoxia-related harm. The strategy has been studied primarily in critical care and post-resuscitation settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: